Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

News Conference News TCT 2017

Novel Percutaneous Suture-Based Solution for PFO Closure Shows Promise

Yael L. Maxwell

October 31, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Daily News

Same-Same but Different? Noninferiority Trials Need a Revamp, NEJM Review Argues

Caitlin E. Cox

October 06, 2017

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

News Daily News

FDA Warns of Rising Endoleak Rates After Endovascular Aneurysm Repair

L.A. McKeown

October 02, 2017

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Daily News

Cuff BP More Variable Than Intra-Arterial Measures

Leah Lawrence

July 25, 2017

News Daily News

Anticoagulation in Pregnant Women With Mechanical Heart Valves: A Balancing Act

Caitlin E. Cox

May 31, 2017

News Industry News

AstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle from That Lot

May 26, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Conference News

Mixed Results, With Some Promising Data, in Heart Failure Destination Therapy Trial

Todd Neale

April 07, 2017

News Daily News

Absorb BVS Use Restricted in Europe

Michael O'Riordan

April 06, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Daily News

FDA Announces Recall of Bard’s Halo One Peripheral Vascular Guiding Sheath

L.A. McKeown

January 31, 2017

Advertisement

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Novel Percutaneous Suture-Based Solution for PFO Closure Shows Promise

Long-term Absorb BVS Data Continue to Disappoint

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Same-Same but Different? Noninferiority Trials Need a Revamp, NEJM Review Argues

Generic ARBs Linked to Increased Adverse Events

FDA Warns of Rising Endoleak Rates After Endovascular Aneurysm Repair

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Cuff BP More Variable Than Intra-Arterial Measures

Anticoagulation in Pregnant Women With Mechanical Heart Valves: A Balancing Act

AstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle from That Lot

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Mixed Results, With Some Promising Data, in Heart Failure Destination Therapy Trial

Absorb BVS Use Restricted in Europe

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

FDA Announces Recall of Bard’s Halo One Peripheral Vascular Guiding Sheath

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content